Responses
EHDN Plenary Meeting: abstracts
Experimental therapeutics: clinical
L05 Huntexil (pridopidine) improves voluntary motor function in patients with Huntington's disease: results from the phase 3 study MermaiHD
Compose a Response to This Article
Other responses
No responses have been published for this article.